Matthew Feinsod - 10 Apr 2025 Form 4 Insider Report for Kalaris Therapeutics, Inc. (KLRS)

Role
Chief Medical Officer
Signature
/s/ Andrew Oxtoby, Attorney-in-Fact
Issuer symbol
KLRS
Transactions as of
10 Apr 2025
Net transactions value
$0
Form type
4
Filing time
11 Apr 2025, 16:52:08 UTC
Previous filing
18 Mar 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KLRS Stock Option (Right to Buy) Award $0 +70,551 $0.000000 70,551 10 Apr 2025 Common Stock 70,551 $7.31 Direct F1
transaction KLRS Stock Option (Right to Buy) Award $0 +101,000 $0.000000 101,000 10 Apr 2025 Common Stock 101,000 $7.31 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
F2 The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.